vTv Therapeutics (NASDAQ:VTVT) reported quarterly earnings of $1.65 per share which beat the analyst consensus estimate of $(0.10) by 1933.33 percent. This is a 314.29 percent increase over losses of $(0.77) per share from the same period last year. The company reported quarterly sales of $36.839 million which beat the analyst consensus estimate of $20.000 million by 84.20 percent.